Therapy Areas: Respiratory
Data from Syndax Pharmaceuticals Clinical Trials Show Increased Immune Responsiveness in NSCLC Patients Treated with Entinostat and Keytruda (pembrolizumab)
13 November 2017 - - US-based biopharmaceutical company Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) has released results from the non-small cell lung cancer (NSCLC) and melanoma cohorts of ENCORE 601 evaluating the combination of entinostat, the company's class I selective HDAC inhibitor, plus Merck's anti-PD-1 (programmed death receptor-1) therapy, Keytruda, the company said.
In data from the first stage of two NSCLC cohorts of ENCORE 601, including patients with PD-(L)1 refractory disease, as well as PD-(L)1 naïve patients, the observed overall response rate was 10% in patients who had progressed on prior anti-PD-1 or PD-(L)1 therapy and 24% in patients naïve to PD-1 or PD-(L)1 therapy.
Across both NSCLC cohorts, the responders with known PD-(L)1 expression levels were all observed to be low (1-49%) or negative expressors. Three patients from each cohort remain on therapy, and two of the six have been on the combination for over one year.
ENCORE 601 is an open-label, Phase 1b/2 clinical trial employing a Simon two-stage design to evaluate four patient populations: patients with non-small cell lung cancer (NSCLC) who have not previously received a PD-1 antagonist; patients with NSCLC who have progressed on a PD-1 antagonist; patients with advanced melanoma who have progressed on a PD-1 antagonist; and microsatellite stable colorectal cancer who have not previously been treated with a PD-1 antagonist.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company that focuses on the development and commercialization of therapies for various cancer indications.
Login
Username:

Password: